MoonLake Immunotherapeutics (MLTX) Current Assets (2020 - 2026)

MoonLake Immunotherapeutics' Current Assets history runs 7 years deep, the most recent figure standing at $396.6 million for Q1 2026.

• On a quarterly basis, Current Assets fell 21.65% year-over-year to $396.6 million in Q1 2026; TTM through Mar 2026 was $396.6 million, a 21.65% decrease from a year earlier, with the FY2025 full-year figure at $421.7 million, down 11.09% from the prior year.
• Current Assets declined to $396.6 million in Q1 2026 per MLTX's latest filing, from $421.7 million in the prior quarter.
• Across five years, Current Assets topped out at $553.6 million in Q1 2024 and bottomed at $66.5 million in Q1 2023.
• The 5-year median for Current Assets is $455.5 million (2025), against an average of $366.8 million.
• Across the five-year window, Current Assets surged 7857.79% in 2022 and sank 42.75% in 2023, its largest moves.
• Year by year, Current Assets stood at $76.5 million in 2022, then surged by 572.01% to $514.2 million in 2023, then slipped by 7.76% to $474.3 million in 2024, then declined by 11.09% to $421.7 million in 2025, then retreated by 5.94% to $396.6 million in 2026.
• Per Business Quant, the three latest MLTX Current Assets figures stand at $396.6 million (Q1 2026), $421.7 million (Q4 2025), and $411.2 million (Q3 2025).